Literature DB >> 19696359

Cyclooxygenase and thromboxane/prostaglandin receptor contribute to aortic endothelium-dependent dysfunction in aging female spontaneously hypertensive rats.

Drew A Graham1, James W E Rush.   

Abstract

Cyclooxygenase (COX)-derived vasoconstrictory prostanoids contribute to impaired endothelium-dependent vasorelaxation in aging male (m) spontaneously hypertensive rats (SHR); however, vasomotor responses in aging female (f) SHR and sex differences in aging SHR are unknown. Examining mechanisms governing dysfunction in aging fSHR will contribute to understanding sex-dependent vascular complications in advanced hypertension. Aortic endothelium-dependent relaxation dose responses (ACh) of 16- and 30-wk-old mSHR and fSHR and normotensive Wistar-Kyoto rats were examined in the absence (no drug control) and presence of COX inhibition [indomethacin (Indo)] and thromboxane/prostaglandin receptor inhibition (SQ-29548). No drug control-treated 16-wk mSHR exhibited considerable blunting of the peak relaxation response to ACh (e.g., 77 +/- 4% relaxation to 10(-5) mol/l) vs. Wistar-Kyoto controls (89 +/- 6%), and greater dysfunction occurred in 30-wk mSHR (63 +/- 2%). Interestingly, ACh relaxations of fSHR were unimpaired at 16 wk (101 +/- 2% to 10(-5) mol/l), but blunted in 30 wk (76 +/- 4%). Indo and SQ-29548 restored robust ACh vasorelaxation in all groups (e.g., 113 +/- 3 and 112 +/- 3%, respectively, in Indo- and SQ-29548-treated 30-wk fSHR). Aortic COX-1 protein expression was elevated by 75% in 30-wk vs. 16-wk fSHR, whereas group-averaged ACh-stimulated aortic PGI(2) release (assessed as 6- keto-PGF(1alpha)) was 30% greater in 30-wk vs. 16-wk fSHR (9,926 +/- 890 vs. 7,621 +/- 690 pg.ml(-1).mg dry wt(-1)), although this did not reach significance (P = 0.0758). Dramatic deterioration of endothelium-dependent vasomotor function in fSHR across this age range involves COX and thromboxane/prostaglandin receptor, supporting a mechanism of impairment similar to that which occurs in aging mSHR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19696359     DOI: 10.1152/japplphysiol.90785.2008

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

Review 1.  Vasoconstrictor prostanoids.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-03-24       Impact factor: 3.657

2.  Chronic in vivo or acute in vitro resveratrol attenuates endothelium-dependent cyclooxygenase-mediated contractile signaling in hypertensive rat carotid artery.

Authors:  Steven G Denniss; Rebecca J Ford; Christopher S Smith; Andrew J Jeffery; James W E Rush
Journal:  J Appl Physiol (1985)       Date:  2016-02-25

3.  Inhibition of delta-6 desaturase reverses cardiolipin remodeling and prevents contractile dysfunction in the aged mouse heart without altering mitochondrial respiratory function.

Authors:  Christopher M Mulligan; Catherine H Le; Anthony B deMooy; Christopher B Nelson; Adam J Chicco
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-01-13       Impact factor: 6.053

4.  Altered hemodynamics, endothelial function, and protein expression occur with aortic coarctation and persist after repair.

Authors:  Arjun Menon; Thomas J Eddinger; Hongfeng Wang; David C Wendell; Jeffrey M Toth; John F LaDisa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-09-28       Impact factor: 4.733

5.  Physical exercise alleviates ADHD symptoms: regional deficits and development trajectory.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2011-08-18       Impact factor: 3.911

6.  Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders.

Authors:  Hao Qian; Na Luo; Yuling Chi
Journal:  J Aging Res       Date:  2012-02-13

Review 7.  Nitric oxide and coronary vascular endothelium adaptations in hypertension.

Authors:  Andrew S Levy; Justin C S Chung; Jeffrey T Kroetsch; James W E Rush
Journal:  Vasc Health Risk Manag       Date:  2009-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.